0001426800 2026-03-19 2026-03-19 0001426800 1 2026-03-19 2026-03-19 0001426800 2 2026-03-19 2026-03-19 0001426800 3 2026-03-19 2026-03-19 0001426800 4 2026-03-19 2026-03-19 0001426800 5 2026-03-19 2026-03-19 0001426800 6 2026-03-19 2026-03-19 0001426800 7 2026-03-19 2026-03-19 0001426800 1 2026-03-19 2026-03-19 0001426800 2 2026-03-19 2026-03-19 iso4217:USD pure S-3 S-3 EX-FILING FEES 0001426800 ASSEMBLY BIOSCIENCES, INC. N/A 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 true false S-3 ASSEMBLY BIOSCIENCES, INC. Equity Common Stock, par value $0.001 per share true Equity Preferred Stock, par value $0.001 per share true Debt Debt Securities true Other Warrants true Other Subscription Rights true Other Units true false Unallocated (Universal) Shelf true 400000000.00 0.0001381 55240.00 400000000.00 55240.00 0.00 13877.69 41362.31 1) Assembly Biosciences, Inc. (the "Company") is hereby registering an indeterminate amount and number of each applicable identified class of the identified securities up to a proposed maximum aggregate offering price of $400,000,000, which may be offered from time to time at indeterminate prices, including securities that may be purchased by underwriters. The Company has estimated the proposed maximum aggregate offering price solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act"). Securities registered hereunder may be sold separately, together or as units with other securities registered hereunder. (2) Pursuant to Rule 416 under the Securities, this registration statement shall also cover any additional shares of the registrant's securities that become issuable by reason of any share splits, share dividends or similar transactions. (3) Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities or preferred stock or upon exercise of common stock warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $400,000,000. (4) Any securities registered under the registration statement may be sold separately or as units with other securities registered under the registration statement. true Assembly Biosciences, Inc. S-3 333-270760 2023-03-22 13877.69 Unallocated (Universal) Shelf Unallocated (Universal) Shelf 125931832.60 true Assembly Biosciences, Inc. S-3 333-270760 2023-03-22 16530.00 Pursuant to Rule 457(p) under the Securities Act, a registration fee of $16,530 was paid with respect to securities available for issuance under a Registration Statement on Form S-3 (File No. 333-270760) filed by the registrant on March 22, 2023 and declared effective on April 14, 2023 (the Prior Registration Statement). The Registrant hereby offsets the total registration fee of $55,240 due under this registration statement by $13,877.69 (calculated at the fee rate in effect at the date of the Prior Registration Statement of $110.20 per million dollars), which represents the portion of the registration fee previously paid with respect to $125,931,832.63 of unsold securities previously registered under the Prior Registration Statement. The offering of the unsold securities registered under the Prior Registration Statement has been terminated. Pursuant to Rule 457(p) under the Securities Act, a registration fee of $16,530 was paid with respect to securities available for issuance under a Registration Statement on Form S-3 (File No. 333-270760) filed by the registrant on March 22, 2023 and declared effective on April 14, 2023 (the Prior Registration Statement). The Registrant hereby offsets the total registration fee of $55,240 due under this registration statement by $13,877.69 (calculated at the fee rate in effect at the date of the Prior Registration Statement of $110.20 per million dollars), which represents the portion of the registration fee previously paid with respect to $125,931,832.63 of unsold securities previously registered under the Prior Registration Statement. The offering of the unsold securities registered under the Prior Registration Statement has been terminated.